Aster DM Healthcare to acquire 20.25% stake in Malabar Institute of Medical Sciences
Aster DM Healthcare approved acquiring an additional 20.25% stake in its subsidiary, Malabar Institute of Medical Sciences (MIMS), to reach 100% ownership. The acquisition is valued at ₹202 per share. MIMS reported ₹1,118.05 crore turnover and ₹134.51 crore profit as of March 31, 2025. The transaction is expected to conclude within three months of dispatching the offer letter.
The acquisition of a material subsidiary aims for 100% ownership, which is a significant step for the company's strategic consolidation. The financial details provided indicate a substantial transaction.
The company is consolidating its shareholding in a subsidiary, which is a positive strategic move towards full ownership and potentially better integration and control.
Aster DM Healthcare Limited announced on January 29, 2026, that its Investment and Finance Committee has approved a proposal to acquire an additional 20.25% equity share capital of its material subsidiary, Malabar Institute of Medical Sciences Limited (MIMS). This acquisition aims to consolidate Aster DM Healthcare's shareholding in MIMS from the current 79.75% to 100%.
The proposed acquisition is structured as a purchase of the equity shares from existing shareholders of MIMS. The transaction will be carried out through a letter of offer, with the actual number of shares purchased dependent on shareholder acceptance. The acquisition is not classified as a related party transaction.
Malabar Institute of Medical Sciences Limited, established on February 17, 1995, is a healthcare services company operating hospitals. As of March 31, 2025, MIMS reported a turnover of ₹1,118.05 crore and a profit of ₹134.51 crore. For the fiscal years 2024 and 2023, MIMS recorded turnovers of ₹1,014.36 crore and ₹899.43 crore, respectively.
The company will dispatch the letter of offer to MIMS shareholders in due course, and the transaction is estimated to be completed within three months from the dispatch date. The cash consideration for the acquisition is ₹202 per share.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.